Global /Taiwan /Healthcare /Biotechnology /4178

StemCyte International, Ltd.

4178

• TPEX: 4178 • Delayed

24.40TWD -4.9%

0.7712 USD

As of 21 June 2026, StemCyte International, Ltd. has a market cap of $148.52M USD, ranking #22927 globally and #1136 in Taiwan. It ranks #2057 in the Healthcare sector, and #395 in the Biotechnology industry.

Global Rank

22927

Country Rank

1136

Sector Rank

2057

Industry Rank

395

Key Stats

Market Cap

$148.52MUSD

4.7B TWD

Enterprise Value

$89.23MUSD

2.82B TWD

Revenue (TTM)

$11.67MUSD

368.91M TWD

EBITDA (TTM)

-$6.22MUSD

-196.93M TWD

Net Income (TTM)

-$5.59MUSD

-176.81M TWD

EBITDA Margin

-53%

Profit Margin

-48%

PS Ratio

12.7

PB Ratio

2.7

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Biotechnology

CEO

Tong-Young Lee open_in_new

Founded

1997

Website

stemcytebio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-4.9%	-2%	-8.6%	-24%	8.4%	-21%	-10%	-47%	-47%

News

Markets

Exchange	Ticker	Price	Quotes
Taipei Exchange (TPEX) MIC: ROCO PRIMARY	4178 StemCyte International Ltd ISIN: KYG8477S1084 Shares Out.: Shares Outstanding: 193.637M¹ TV: TradingView: TPEX: 4178 SA: Stock Analysis: TPEX: 4178 YF: Yahoo Finance: 4178.TWO GF: Google Finance: TPEX: 4178 BA: Barron's: 4178 MS: Morningstar: ROCO: 4178	24.40 TWD	TV: TradingView: TPEX: 4178 SA: Stock Analysis: TPEX: 4178 YF: Yahoo Finance: 4178.TWO GF: Google Finance: TPEX: 4178 BA: Barron's: 4178 MS: Morningstar: ROCO: 4178
Taiwan Stock Exchange (TWSE) MIC: XTAI	4178 StemCyte International Ltd ISIN: KYG8477S1084 TV: TradingView: TWSE: 4178 SA: Stock Analysis: TPE: 4178 YF: Yahoo Finance: 4178.TW GF: Google Finance: TPE: 4178 BA: Barron's: 4178 MS: Morningstar: XTAI: 4178	19.10 TWD	TV: TradingView: TWSE: 4178 SA: Stock Analysis: TPE: 4178 YF: Yahoo Finance: 4178.TW GF: Google Finance: TPE: 4178 BA: Barron's: 4178 MS: Morningstar: XTAI: 4178

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About StemCyte International, Ltd.

StemCyte International, Ltd., a biotechnology company, develops cord blood–based cell therapies in the United States and Taiwan. The company engages in the research and development of biotechnology and cell-based new drugs; supply of cellular materials; and operation of cord blood cell banks. It also offers umbilical cord blood transplantation services; and cell products and services. In addition, the company provides REGENECYTE, an allogeneic umbilical cord blood cellular biotherapy for the treatment of cancer, hematological disorders, immune-related conditions, and metabolic disorders, as well as for post-covid, acute stroke, and cerebral palsy. Further, it develops CB201(CB-NK), an API in preclinical development for the treatment of hematological malignancies. The company was founded in 1997 and is based in Taipei, Taiwan. StemCyte International, Ltd. operates as a subsidiary of Diamond Biofund Inc.

Similar Companies

Industry: Biotechnology (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
Caliway Biopharmaceuticals Co., Ltd. TWSE: 6919	$5.46B 172.76B TWD 4K%	-	Taiwan
Pell Bio-Med Technology Co., Ltd. TWSE: 6949	$1.61B 50.93B TWD 984%	-	Taiwan
Lin BioScience, Inc. TPEX: 6696	$1.08B 34.04B TWD 625%	-	Taiwan
HanchorBio Inc. TWSE: 7827	$726.25M 22.97B TWD 389%	-	Taiwan
HanchorBio Inc. TPEX: 7827	$600.25M 18.98B TWD 304%	-	Taiwan
Locus Cell Co., Ltd. TPEX: 06891	$571.26M 18.06B TWD 285%	-	Taiwan

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 123K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 108K%	19.0	United States
argenx SE EBR: ARGX	$47.43B 41.39B EUR 32K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.23B 68.19T KRW 30K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.27B 60.27B AUD 28K%	29.3	Australia
Lonza Group AG SIX: LONN	$41.88B 33.71B CHF 28K%	37.2	Switzerland

chevron_leftBack